Myeloma News and Research

RSS

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Ligand Pharmaceuticals Incorporated today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib.

22 Oct 2012

R848 chemical can prime the immune system to fight lymphoma

UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

From The University of Manchester 20 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.

8 Oct 2012

Loyola oncologist named ‘Heroes of Hope’ by Leukemia Research Foundation

The Leukemia Research Foundation has named Loyola University Medical Center oncologist Dr. Tulio Rodriguez one of its "Heroes for Hope."

4 Oct 2012

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.

2 Oct 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.

28 Sep 2012

New understanding about function of MYC proteins

Scientists may have discovered why a protein called MYC can provoke a variety of cancers. Like many proteins associated with cancer, MYC helps regulate cell growth. A study carried out by researchers at the National Institutes of Health and colleagues found that, unlike many other cell growth regulators, MYC does not turn genes on or off, but instead boosts the expression of genes that are already turned on.

28 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

InterCure signs strategic service agreement with private company

XTL Biopharmaceuticals Ltd. today announced that InterCure Ltd., which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur.

25 Sep 2012

FDA Oncologic Drugs Advisory Committee to review Celgene’s pomalidomide NDA on Nov. 8

Celgene Corporation today announced the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee will hold a review of the Company's new drug application (NDA) for pomalidomide at its meeting on November 8, 2012.

20 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance."

17 Sep 2012

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

Senesco Technologies, Inc. reported today that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with SNS01-T in multiple myeloma.

14 Sep 2012

NDC to advance study and treatment of Alzheimer's and other neurodegenerative diseases

The Neurodegeneration Consortium (NDC), a transformative multi-institutional initiative, will advance the study and treatment of Alzheimer's and other neurodegenerative diseases, thanks to an inaugural $25 million gift from the Robert A. and Renee E. Belfer Family Foundation to The University of Texas MD Anderson Cancer Center, Baylor College of Medicine and the Massachusetts Institute of Technology (MIT).

13 Sep 2012

Myeloma News and Research

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

R848 chemical can prime the immune system to fight lymphoma

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Loyola oncologist named ‘Heroes of Hope’ by Leukemia Research Foundation

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

Synta announces results from ganetespib Phase 2b trial on NSCLC

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

New understanding about function of MYC proteins

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

InterCure signs strategic service agreement with private company

FDA Oncologic Drugs Advisory Committee to review Celgene’s pomalidomide NDA on Nov. 8

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

NDC to advance study and treatment of Alzheimer's and other neurodegenerative diseases

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News